The government has proposed an amendment that would allow for the immediate suspension of manufacturing licences in cases involving substandard drugs.
According to the proposal, mandatory corrective measures would have to be taken before any suspension is revoked. The suspension would remain in force until the manufacturer undertakes the required corrective action.
The move is intended to tighten action against the production of substandard medicines and ensure compliance with quality norms. Further details on the amendment and its implementation timeline were not specified in the input.
